Eli Lilly's weight-loss drug Zepbound generated $5 billion in quarterly revenue, marking a 50% year-over-year increase

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.